检索时限起始于1990年1月,截至2023年8月,英文文献检索词主要包括BRCA1/2、hereditary breast cancer、hereditary ovarian cancer、germline mutation、screening test、population screening、BRCAscreening、cancer risk assessment、cancer susceptib...
“This test provides information to certain individuals who may be at increased breast, ovarian or prostate cancer risk and who might not otherwise get genetic screening, and is a step forward in the availability of DTC genetic tests. But it has a lot of caveats,” said Donald St. Pierre, ...
specificBRCA-targeted therapies, such as PARPi, are found to be effective in the presence ofBRCA1/2m alone. Of note, although these mutations are uncommon in prostate cancer, data suggest that patients with somaticBRCA1/2m will respond to PARPi.27The efficacy of PARPi for advanced BC with ...
Prostate-specific antigen (PSA) test to check for prostate cancer Imaging tests like MRI or ultrasound to check for pancreatic cancer Questions for your doctor about test results It may be helpful to ask your doctor or genetic counselor these questions: What do my test results say about my can...
One new prostate cancer case occurs every 2.1 minutes (American Cancer Society, 2013). The purpose of this study was to design and test a reliable and valid survey instrument for assessing male perception of prostate cancer, identify factors affecting male perception if a carrier for the Breast ...
Additionally, the test detects prostate, pancreatic, and male breast cancer. So, don’t be too surprised if you’re asked to take the test for anything other than breast cancer.2 3. Breast Cancer Patients Must Take It The BRCA test isn’t just done to detect the risk of breast cancer....
for BRCA germline mutation screening in the Chinese population, a consensus development group was established by the China Anti-Cancer Association Tumor Biomarker Professional Committee and the Shanghai Anti-Cancer Association Tumor Biomarker Professional Committee. Using an evidence-based approach and ...
forBRCAgermline mutation screening in the Chinese population, a consensus development group was established by the China Anti-Cancer Association Tumor Biomarker Professional Committee and the Shanghai Anti-Cancer Association Tumor Biomarker Professional Committee. Using an evidence-based approach and building...
prostate cancer, pancreatic cancer, and breast cancer in males. There has also been a rapid expansion of US Food and Drug Administration–approved targeted cancer therapies, including poly ADP ribose polymerase (PARP) inhibitors, for breast, pancreatic, and prostate cancers associated withBRCA1/2PVs...
3Department of Dermatology, University of Utah, Salt Lake City, Utah 84132, USA; 4The Royal Marsden NHS Foundation Trust, London SM2 5NG, UK BACKGROUND: A family history of prostate cancer (PrCa) is a strong risk factor for the disease, indicating that inherited factors are important in th...